Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 285-292

  Bordia, Tanuja ^a   Parameswaran, Neeraja ^a   Fan, Hong ^b   Langston, J William ^a   McIntosh, J Michael ^c   Quik, Maryka ^a  

^a PARKINSON S INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; CONOTOXIN; EPIBATIDINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; MONKEY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION;

ANIMALS; AZETIDINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; CONOTOXINS; CORPUS STRIATUM; FEMALE; MPTP POISONING; NICOTINE; PARKINSON DISEASE; PYRIDINES; RECEPTORS, NICOTINIC; SAIMIRI;

EID: 33749009597     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106997     Document Type: Article

References (40)

1. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, and Fernandez-Crehuet Navajas R (2004) Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 19:614-621.
2. 3H]nicotine binding sites in human brain. J Neurochem 50:1243-1247.
3. 125I]α-bungarotoxin binding in human postmortem brain. J Comp Neurol 387:385-398.
4. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, and McIntosh JM (1996) A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. J Biol Chem 271:7522-7528.
5. Dajas-Bailador F and Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 25:317-324.
6. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J Pharmacol Exp Ther 282:445-451.
7. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, and Poewe W (1999) Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 14:1011-1013.
8. Fagerstrom KO, Pomerleau O, Giordani B, and Stelson F (1994) Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 116:117-119.
9. Gotti C and Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363-396.
10. Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, Marks MJ, and Whiteaker P (2005) Expression of nigrostriatal α6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by β3 subunit gene deletion. Mol Pharmacol 67:2007-2015.
11. Hukkanen J, Jacob P 3rd, and Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79-115.
12. Ishikawa A and Miyatake T (1993) Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 117:28-32.
13. Jones IW and Wonnacott S (2004) Precise localization of α7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24:11244-11252.
14. Kelton MC, Kahn HJ, Conrath CL, and Newhouse PA (2000) The effects of nicotine on Parkinson's disease. Brain Cogn 43:274-282.
15. Kulak JM, McIntosh JM, and Quik M (2002a) Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in α-conotoxin MII sites. Mol Pharmacol 61:230-238.
16. Kulak JM, Musachio JL, McIntosh JM, and Quik M (2002b) Declines in different β2* nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther 303:633-639.
17. Lai A, Parameswaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, McIntosh JM, Grady SR, and Quik M (2005) Long-term nicotine treatment decreases striatal α6* nicotinic acetylcholine receptor sites and function in mice. Mol Pharmacol 67:1639-1647.
18. Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, and Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31-39.
19. Marks MJ, Burch JB, and Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226:817-825.
20. McCallum SE, Parameswaran N, Bordia T, Fan H, Tyndale RF, Langston JW, McIntosh JM, and Quik M (2006) Increases in α4* but not α3*/α6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem 96:1028-1041.
21. McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, and Quik M (2005) Decrease in α3*/α6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol Pharmacol 68:737-746.
22. Morens DM, Grandinetti A, Reed D, White LR, and Ross GW (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-1051.
23. 125I]α-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. Neuroscience 137:565-572.
24. Nguyen HN, Rasmussen BA, and Perry DC (2003) Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther 307:1090-1097.
25. O'Neill MJ, Murray TK, Lakics V, Visanji NP, and Duty S (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Target CNS Neurol Disord 1:399-411.
26. Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, Lindstrom JM, and Sharp BM (2004) Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the α6 subunit. Mol Pharmacol 65:611-622.
27. Perry DC, Davila-Garcia MI, Stockmeier CA, and Kellar KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 289:1545-1552.
28. Quik M (2004) Smoking, nicotine and Parkinson's disease. Trends Neurosci 27:561-568.
29. Quik M, Bordia T, Okihara M, Fan H, Marks MJ, McIntosh JM, and Whiteaker P (2003) L-DOPA Treatment Modulates Nicotinic Receptors in Monkey Striatum. Mol Pharmacol 64:619-628.
30. Quik M, Chen L, Parameswaran N, Xie X, Langston JW, and McCallum SE (2006a) Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in MPTP-lesioned primates. J Neurosci 26:4681-4689.
31. Quik M and McIntosh JM (2006b) Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 316:481-489.
32. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, Kim A, Tyndale RF, Langston JW, and Di Monte DA (2006c) Chronic oral nicotine treatment protects against striatal degeneration in monkey brain. J Neurochem, in press.
33. 125I-α-conotoxin MII binding sites to nigrostriatal damage in monkey. J Neurosci 21:5494-5500.
34. Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, Clementi F, and Gotti C (2005) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. Mol Pharmacol 67:32-41.
35. Salminen O, Grady SR, Collins AC, McIntosh JM, and Marks MJ (2004a) Chronic nicotine infusion down regulates α-conotoxin MII sensitive nicotinic acetylcholine receptors in C57bl/6 mice. Program No. 48.21. Abstract Viewer/Itinerary Planner; 2004 Oct 23-27; San Diego, CA. Society for Neuroscience, Washington, DC.
36. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, and Grady SR (2004b) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65:1526-1535.
37. Schwartz RD and Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science (Wash DC) 220:214-216.
38. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, and Vieregge P (2001) Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 57:1032-1035.
39. Wonnacott S, Sidhpura N, and Balfour DJ (2005) Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5:53-59.
40. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, and Gotti C (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 22:8785-8789.